Evidence map›Paper›PMID 40927406›Full record

ArticleFASEB bioAdvances2025

Monoclonal Antibody 5F1 Modulates Formyl Peptide Receptor 1 Conformation for Transmembrane Signaling.

Yue Wang, Yezhou Liu, Yixin Chang, Richard D Ye

Abstract read
In one paragraph

Article in FASEB bioAdvances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yue WangKobilka Institute of Innovative Drug Discovery, School of Medicine The Chinese University of Hong Kong Shenzhen Guangdong China.ORCID https://orcid.org/0000-0001-5386-971X
Yezhou LiuKobilka Institute of Innovative Drug Discovery, School of Medicine The Chinese University of Hong Kong Shenzhen Guangdong China.ORCID https://orcid.org/0000-0001-7575-8260
Yixin ChangKobilka Institute of Innovative Drug Discovery, School of Medicine The Chinese University of Hong Kong Shenzhen Guangdong China.ORCID https://orcid.org/0009-0002-8518-8470
Richard D YeKobilka Institute of Innovative Drug Discovery, School of Medicine The Chinese University of Hong Kong Shenzhen Guangdong China.ORCID https://orcid.org/0000-0002-2164-5620

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Formyl peptide receptor 1 (FPR1) is a G protein-coupled receptor (GPCR) that mediates chemotaxis and bactericidal activities in phagocytes. The monoclonal antibody 5F1 is generated against full-length FPR1 and used widely for detection of FPR1 expression. This study aimed to characterize 5F1 for its functions. We found that 5F1 is highly selective for human FPR1 over the homologous FPR2. Epitope mapping led to the identification of extracellular loop 2 (ECL2) as a major epitope, and the synthetic peptide of ECL2 interfered with 5F1 binding to FPR1. Using a NanoLuc Bioluminescence Resonance Energy Transfer approach, we found that 5F1 binding induced FPR1 conformational changes. Although less potent than fMLF, 5F1 binding induced FPR1 internalization, Gi protein dissociation, and β-arrestins membrane translocation. Alanine substitution of F110 and R205 markedly reduced 5F1 binding without affecting FPR1 cell surface expression, suggesting that 5F1 is sensitive to conformational changes in FPR1 as these residues are not present in ECL2. Altogether, mAb 5F1 can alter FPR1 conformation and modulate transmembrane signaling, features that may be explored for potential use beyond the detection of FPR1 expression.

Indexed as

antibodybiased agonismformyl peptide receptorGPCRreceptor conformation

Identifiers

PMID40927406
PMCPMC12415353

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.